Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$124.00

-2.57 (-2.03%)

08:55
03/25/19
03/25
08:55
03/25/19
08:55

Sarepta rallies after presenting 9-month DMD gene therapy data

Sarepta Therapeutics presented this morning nine-month functional and creatine kinase data from baseline from the four patients in the Phase 1 open-label study of the company's micro-dystrophin gene therapy candidate for Duchenne muscular dystrophy. The biomarkers show "large" magnitude of effect within three months for both CK and dystrophin, Sarepta said. Further, initial functional data shows "consistent and persistent" improvement from baseline to day 270, the company adds. Sarepta also sees a "favorable" safety profile to date with nine months of follow-up. The company is currently enrolling Study-102, which contains 24 patients and is placebo controlled. Shares of Sarepta are up 3%, or $3.94, to $126.20 in premarket trading. Reference Link

  • 25

    Mar

  • 19

    Aug

SRPT Sarepta
$124.00

-2.57 (-2.03%)

03/06/19
PIPR
03/06/19
NO CHANGE
Target $200
PIPR
Overweight
Sarepta selloff on short report a buying opportunity, says Piper Jaffray
A short report on Sarepta Therapeutics was published this morning and appears to be the reason for today's selloff, Piper Jaffray analyst Danielle Brill tells investors in a research note. After going through the report, however, the analyst found "no salient points to consider," and she remains confident in her Overweight thesis on the shares. The LGMD-2E data presented last week sufficiently demonstrated proof-of-concept and further de-risked Sarepta's muscle targeted gene therapy platform, says Brill. She believes the company's fundamentals remain intact and would be a buyer on today's selloff. The analyst reiterates an Overweight rating on Sarepta with a $200 price target. The stock in midday trading is down 9%, or $13.21, to $135.38. The short report, while not mentioned by name in Piper's research note, is said to be from Elliot Favus of Favus Institutional Research. In addition, a secondary offering of 2.6M Sarepta shares priced last night at $144.00.
03/07/19
CANT
03/07/19
NO CHANGE
Target $231
CANT
Overweight
Sarepta sees slight bounce back after Cantor calls selloff unwarranted
Shares of Sarepta Therapeutics are bouncing back slightly following yesterday's 11% selloff. The weakness yesterday stemmed from Tuesday's night capital raise as well as the resignation of FDA Commissioner Scott Gottlieb, and, to a lesser extent, a new short report, Cantor Fitzgerald analyst Alethia Young told investors last night in a research note. On the short report, the analyst disagrees with her understanding of its key points, and particularly thinks increasing the betasarcoglycan protein will lead to functional change over time. Sarepta has a clear lead in Duchenne muscular dystrophy gene therapy and its data has set a high bar for competition, Young wrote. Further, she thinks that if demand is available and companies can get capital they do. As such, the analyst is unconcerned by Tuesday's equity raise. As it relates to Dr. Gottlieb's departure, Young notes that Dr. Woodcock, who has been supportive of DMD, is still at the agency. All today, the analyst views yesterday's selloff as unwarranted and reiterated Sarepta as one of her top 2019 picks. She has an Overweight rating on the shares with a $231 price target. Sarepta in late morning trading is up 2%, or $2.38, to $134.63.
03/11/19
FBCO
03/11/19
NO CHANGE
Target $207
FBCO
Outperform
Sarepta price target raised to $207 from $189 at Credit Suisse
Credit Suisse analyst Martin Auster maintained an Outperform rating on Sarepta (SRPT) and raised his price target to $207 from $189. In a research note to investors, Auster says his bull thesis has strengthened further, and that he is growing increasingly comfortable that the company's Duchenne Muscular Dystrophy program may provide to be first-in-class as well as best-in-class. He sees the completion of Sarepta's manufacturing scale-up allowing for commencement of the confirmatory Phase 3 trial in late 2019 and initial Phase 1/2 data from Pfizer (PFE) in its DMD gene tx trial in Q3 as critical catalysts to drive share appreciation of the next nine months.
03/12/19
PIPR
03/12/19
NO CHANGE
PIPR
Biopharma stocks should be up sharply on Sharpless selection, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond said he expects biopharma stocks to be up sharply on news that former National Cancer Institute director Ned Sharpless will be named acting FDA commissioner. The biotech sector "experienced a swoon of sorts" since Scott Gottlieb announced his departure, but with the announcement of Gottlieb's favored choice as successor Raymond believes the FDA will remain "on its current industry-friendly and efficiency driven trajectory," the analyst tells investors.

TODAY'S FREE FLY STORIES

09:58
12/09/19
12/09
09:58
12/09/19
09:58
Conference/Events
JPMorgan oil services/equip analyst to hold an analyst/industry conference call »

Oil Services &…

PCG

PG&E

$11.30

1.65 (17.10%)

, SIG

Signet Jewelers

$21.05

0.48 (2.33%)

09:55
12/09/19
12/09
09:55
12/09/19
09:55
Options
Early notable gainers among liquid option names on December 9th »

Notable gainers among…

PCG

PG&E

$11.30

1.65 (17.10%)

SIG

Signet Jewelers

$21.05

0.48 (2.33%)

SWKS

Skyworks

$104.20

2.8 (2.76%)

FCX

Freeport McMoRan

$11.97

0.33 (2.84%)

FTV

Fortive

$75.51

2.65 (3.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 07

    Jan

09:55
12/09/19
12/09
09:55
12/09/19
09:55
Conference/Events
JPMorgan homebuilding analyst to hold an analyst/industry conference call »

Homebuilding &…

09:55
12/09/19
12/09
09:55
12/09/19
09:55
Conference/Events
JPMorgan business services analyst to hold analyst/industry conference call »

Business &…

FTSV

Forty Seven

$17.61

3.21 (22.29%)

09:53
12/09/19
12/09
09:53
12/09/19
09:53
Hot Stocks
Breaking Hot Stocks news story on Forty Seven »

Forty Seven trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

TTWO

Take-Two

$119.55

-4.21 (-3.40%)

09:53
12/09/19
12/09
09:53
12/09/19
09:53
Recommendations
Take-Two analyst commentary  »

Take-Two's BioShock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 13

    Dec

HY

Hyster-Yale Materials

$60.47

0.66 (1.10%)

09:52
12/09/19
12/09
09:52
12/09/19
09:52
Conference/Events
Hyster-Yale Materials management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 26

    Feb

ZS

Zscaler

$47.38

0.66 (1.41%)

09:50
12/09/19
12/09
09:50
12/09/19
09:50
Options
Funky call sale in ZScaler at market-open »

Funky call sale in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 16

    Dec

RTRX

Retrophin

$13.31

0.05 (0.38%)

09:50
12/09/19
12/09
09:50
12/09/19
09:50
Conference/Events
Retrophin management to meet with JMP Securities »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

ARQL

ArQule

$19.61

9.94 (102.79%)

, LLY

Eli Lilly

$119.52

-0.07 (-0.06%)

09:49
12/09/19
12/09
09:49
12/09/19
09:49
Conference/Events
Wolfe Research biotech analyst to hold an analyst/industry webcast »

Biotech Analyst Tewari…

ARQL

ArQule

$19.61

9.94 (102.79%)

LLY

Eli Lilly

$119.52

-0.07 (-0.06%)

MRK

Merck

$88.76

-0.08 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 11

    Dec

  • 17

    Dec

  • 17

    Dec

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 05

    Feb

  • 14

    Mar

XFOR

X4 Pharmaceuticals

$10.60

(0.00%)

09:48
12/09/19
12/09
09:48
12/09/19
09:48
Upgrade
X4 Pharmaceuticals rating change  »

X4 Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTSV

Forty Seven

$15.86

1.46 (10.14%)

09:48
12/09/19
12/09
09:48
12/09/19
09:48
Hot Stocks
Breaking Hot Stocks news story on Forty Seven »

Forty Seven trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

KOS

Kosmos

$5.41

-0.62 (-10.28%)

09:47
12/09/19
12/09
09:47
12/09/19
09:47
Hot Stocks
Kosmos falls -10.6% »

Kosmos is down -10.6%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UGAZ

VelocityShares 3x Long Natural Gas ETN

$7.93

-1.42 (-15.19%)

09:47
12/09/19
12/09
09:47
12/09/19
09:47
Hot Stocks
VelocityShares 3x Long Natural Gas ETN falls -15.2% »

VelocityShares 3x Long…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPLO

Diplomat Pharmacy

$3.97

-1.855 (-31.87%)

09:47
12/09/19
12/09
09:47
12/09/19
09:47
Hot Stocks
Diplomat Pharmacy falls -31.7% »

Diplomat Pharmacy is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPCE

Virgin Galactic

$8.04

0.76 (10.44%)

09:47
12/09/19
12/09
09:47
12/09/19
09:47
Hot Stocks
Virgin Galactic rises 10.4% »

Virgin Galactic is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

PCG

PG&E

$11.05

1.4 (14.51%)

09:47
12/09/19
12/09
09:47
12/09/19
09:47
Hot Stocks
PG&E rises 14.7% »

PG&E is up 14.7%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$180.50

24.71 (15.86%)

09:47
12/09/19
12/09
09:47
12/09/19
09:47
Hot Stocks
VelocityShares 3x Inv Natural Gas ETN rises 16.0% »

VelocityShares 3x Inv…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBB

RBB Bancorp

$20.42

(0.00%)

09:45
12/09/19
12/09
09:45
12/09/19
09:45
Conference/Events
RBB Bancorp management to meet with Sandler O'Neill »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

  • 12

    Dec

09:45
12/09/19
12/09
09:45
12/09/19
09:45
General news
Treasury 3-year auction outlook: the $38 B sale leads off »

Treasury 3-year auction…

TTWO

Take-Two

$123.76

(0.00%)

09:44
12/09/19
12/09
09:44
12/09/19
09:44
Hot Stocks
Take-Two says newly-formed 'Cloud Chamber' studio developing next BioShock game »

2K, a publishing label of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 13

    Dec

ALPN

Alpine Immune Sciences

$3.02

(0.00%)

09:40
12/09/19
12/09
09:40
12/09/19
09:40
Hot Stocks
Alpine Immune Sciences presents ALPN-101 Phase 1 healthy volunteer study data »

Alpine Immune Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JBLU

JetBlue

$19.03

(0.00%)

, SPCE

Virgin Galactic

$7.28

(0.00%)

09:40
12/09/19
12/09
09:40
12/09/19
09:40
Options
Unusually active option classes on open December 9th »

Unusual total active…

JBLU

JetBlue

$19.03

(0.00%)

SPCE

Virgin Galactic

$7.28

(0.00%)

CHWY

Chewy

$24.93

(0.00%)

VLO

Valero

$93.62

(0.00%)

DELL

Dell Technologies

$47.09

(0.00%)

CRWD

Crowdstrike

$50.89

(0.00%)

ZS

Zscaler

$46.72

(0.00%)

LULU

Lululemon

$229.50

(0.00%)

CGC

Canopy Growth

$18.65

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 11

    Dec

  • 12

    Dec

  • 16

    Dec

  • 27

    Feb

  • 09

    Dec

KALV

KalVista

$14.36

0.25 (1.77%)

, MRK

Merck

$88.84

0.09 (0.10%)

09:37
12/09/19
12/09
09:37
12/09/19
09:37
Recommendations
KalVista, Merck analyst commentary  »

Roth says KalVista trial…

KALV

KalVista

$14.36

0.25 (1.77%)

MRK

Merck

$88.84

0.09 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

  • 17

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

PSTL

Postal Realty Trust

$15.85

0.15 (0.96%)

09:34
12/09/19
12/09
09:34
12/09/19
09:34
Conference/Events
Postal Realty Trust management to meet with DA Davidson »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.